Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin G. Drusano Clinical Microbiology and Infection Volume 7, Pages 24-29 (January 2001) DOI: 10.1046/j.1469-0691.2001.0070s3024.x Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions
Fig 1 Plasma concentration-time profile of telithromycin after single and 10 days' once-daily administration of 800 mg to 12 healthy young subjects [12]. ery-R, erythromycin resistant; ery-S, erythromycin susceptible; peni-R, penicillin resistant; LOQ, limit of quantification. Clinical Microbiology and Infection 2001 7, 24-29DOI: (10.1046/j.1469-0691.2001.0070s3024.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions
Fig 2 Telithromycin plasma concentration-time profile following an oral 800 mg dose of telithromycin taken after either an overnight fast or a standard high-fat breakfast [14]. Clinical Microbiology and Infection 2001 7, 24-29DOI: (10.1046/j.1469-0691.2001.0070s3024.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions
Fig 3 Mean concentration of telithromycin in epithelial lining fluid (ELF) and plasma following telithromycin 800 mg once daily for 5 days in 24 healthy volunteers [17]. Clinical Microbiology and Infection 2001 7, 24-29DOI: (10.1046/j.1469-0691.2001.0070s3024.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions